Anxu Bio: Net profit of 73.3821 million yuan in 2025, down 61.84% year-on-year

Anxu Biology released its performance report, with the company achieving an operating income of 454 million yuan for the fiscal year 2025, a year-on-year decrease of 16.11%; net profit was 73.3821 million yuan, a year-on-year decrease of 61.84%. During this reporting period, the company focused on the goal of steady development of its main business, integrating existing high-quality technology resources, and continuously increasing strategic investment in new technology platforms, steadily advancing product registration and certification work both domestically and internationally, further consolidating its long-term competitive advantages in the industry. At the same time, the company is deeply promoting an operational upgrade centered on lean management, continuously enhancing operational efficiency and cost control capabilities, with significant improvements in quality and efficiency. In terms of international strategy, the company continues to strengthen the layout of overseas branches, achieving positive progress in expanding overseas markets, with corresponding sales expenses increasing, opening up space for sustained growth in the future.